Physician profile
Stephen G Cunningham
NPI 1780855114
$10,021.17
in general payments reported to CMS, 2019-2025
25 companies · $2,781 in 2025
The $2,781 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $373 · 2021: $970 · 2022: $1,423 · 2023: $1,544 · 2024: $2,155 · 2025: $2,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,479.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,847.44 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $1,200.08 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $1,144.87 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $971.33 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $870.55 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $669.36 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $653.57 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $439.40 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $418.31 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $257.60 | 2024-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $211.02 | 2020-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.86 | 2022-2025 | Caplyta |
| Braeburn INC. | $152.71 | 2023-2025 | Brixadi |
| Tris Pharma INC | $147.17 | 2023-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $143.19 | 2022-2025 | Adzenys Xr-Odt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $142.37 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $134.25 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $126.44 | 2020-2025 | Fanapt |
| Indivior INC. | $63.90 | 2020-2025 | Sublocade |
| Allergan, INC. | $61.29 | 2020-2021 | |
| Lundbeck LLC | $55.51 | 2024 | Rexulti |
| Almatica Pharma LLC | $53.64 | 2021-2022 | |
| Eisai INC. | $30.96 | 2020 | |
| Biogen, INC. | $24.91 | 2024 | Zurzuvae |
| Noven Therapeutics, LLC | $19.44 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.